ALTO insider James Sneed buys 3,176 shares at $1.0593
Alto Ingredients insider James R. Sneed, the company’s Chief Commercial Officer and a director, purchased 3,176 shares of common stock at $1.0593 per share on 08/13/2025.
Rhea-AI Filing Summary
Alto Ingredients insider James R. Sneed, the company’s Chief Commercial Officer and a director, purchased 3,176 shares of common stock at $1.0593 per share on 08/13/2025. After the transaction he directly beneficially owns 432,397 shares. The Form 4 reports this routine insider acquisition and shows no derivatives or other transactions.
Positive
- None.
Negative
- None.
Insights
TL;DR: Small insider purchase increases direct stake to 432,397 shares; transaction appears routine and not materially transformative.
The reported purchase of 3,176 shares at $1.0593 is a modest open-market acquisition by a senior officer and director. Given the size relative to total post-transaction holdings, this disclosure is informative about insider activity but unlikely to materially affect valuation or capital structure. No derivative positions or dispositions were reported, limiting complexity.
TL;DR: Insider compliance is evident; the filing documents a standard Section 16 disclosure for an officer/director purchase.
The Form 4 is properly signed and indicates the reporting person filed individually. The transaction code shows a purchase (P) and the filing records direct ownership. There are no indications of coordinated group filings, plans, or Rule 10b5-1 reliance in the reported fields. This represents routine transparency under insider trading rules.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 3,176 | $1.0593 | $3K |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did James R. Sneed report for ALTO?
Did the Form 4 report any derivative securities or option transactions for ALTO?
What is James R. Sneed’s role at Alto Ingredients (ALTO)?
AI-generated analysis. How Rhea-AI works. Not financial advice.